Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Cánceres Gastrointestinal / Cáncer del Colon y Recto / Recursos de NCI
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - October 2001
Motivations and psychosocial impact of genetic testing for HNPCC. Genotype and phenotype of a new 2-bp deletion of hMSH2 at codon 233. Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study.... |
|
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - September 2001
Table of ContentsCYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer.Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability.DNA variants of BAT-25 in... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - October 2001
Reconstruction of perianal skin defect using a V-Y advancement of bilateral gluteus maximus musculocutaneous flaps: reconstruction The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Conservative... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - September 2001
Table of Contents[Diagnosis, therapy, and follow up in synchronous colorectal cancer of the colon][Intraoperative radiotherapy--progress with a CT-assisted navigation system][Transanal endoscopic microsurgery: a forgotten minimally invasive ... |
|
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - April 2002
[Colorectal carcinoma and molecular genetics] [Search for microsatellite instability in colorectal cancer: an effective way to detect HNPCC?] [Specialized genetic counseling in pediatric and adult oncology patients] Mutations of hMLH1 and... |
|
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - August 2002
Hereditary non-polyposis colorectal cancer (HNPCC): phenotype-genotype correlation between patients with and without identified mutation. Missense mismatch repair gene alterations, microsatellite instability, and hereditary nonpolyposis... |
|
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - February 2002
Comprehension of cancer risk one and 12 months after predictive genetic testing for hereditary non-polyposis colorectal cancer. Cancer genetics in oncology practice. Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a ... |
|
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - January 2002
Four novel MSH2 and MLH1 frameshift mutations and occurrence of a breast cancer phenocopy in hereditary nonpolyposis colorectal cancer. Hereditary and somatic DNA mismatch repair gene mutations in sporadic endometrial carcinoma. Structure... |
|
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - July 2002
Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic Clinical characteristics of Taiwanese hereditary non-polyposis colorectal cancer kindreds. Endometrial... |
|
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - June 2002
Clinicopathological and molecular genetic analysis of 4 typical Chinese HNPCC families. High frequency of microsatellite instability and loss of mismatch-repair protein expression in patients with double primary tumors of the Evolution... |
|
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - March 2002
Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms. MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal... |
|
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - May 2002
Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative Familial colorectal adenocarcinoma from the Swedish Family-Cancer Database. Familial and inherited... |
|
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - October 2002
Endometrial abnormalities in three sisters from a family with hereditary non-polyposis colorectal cancer syndrome. The genetics of colorectal cancer. Summaries for patients. The genetics of colorectal cancer. Functional analysis of MSH6... |
|
|
NCI CANCERLIT® Search: Non-polyposis Colon Cancer, Hereditary - September 2002
hMLH1 and hMSH2 mutations in families with familial clustering of gastric cancer and hereditary non-polyposis colorectal cancer. hMLH1 and hMSH2 gene mutation in Brazilian families with suspected hereditary nonpolyposis colorectal cancer.... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - April 2002
Prospective evaluation of omentoplasty in preventing leakage of colorectal anastomosis. [Familial colonic polyposis: effect of molecular analysis on the diagnostic-therapeutic approach] Preoperative neoadjuvant therapy for rectal cancer... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - August 2002
Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells. Perioperative radiotherapy in rectal cancer. Radiotherapy in rectal cancer. Indications for and results... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - February 2002
Lymphatic mapping improves staging during laparoscopic colectomy for cancer. [Morphological aspects of intense preoperative hypoxyradiotherapy in combined treatment of patients with sigmoid colon carcinoma] Capecitabine: a review of its... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - January 2002
Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: effect... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - July 2002
A phase I study of immunostimulation and toxicity in patients with colorectal carcinoma using the immunomodulator Transient P-cadherin expression in radiation proctitis; a model of mucosal injury and repair. Nucleoside transport... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - June 2002
[Resection of liver metastasis: higher chance of survival] Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed? Prognostic significance of nodal disease following preoperative radiation for... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - March 2002
'Hold the Mayo': solid facts or pulp fiction? Combination chemotherapy for colon cancer: de gustibus non est disputandum. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. Cellular and humoral... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - May 2002
Nothing succeeds like failure. Hand-assisted laparoscopic low anterior resection: initial experience with a new procedure. Older age--not a barrier to cancer treatment. Impaired sphincter function and good quality of life in anal carcinoma ... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - October 2002
[Locoregional immunotherapy of malignant effusions for colorectal cancer using OK-432 and its acting mechanisms--possibility of molecular Prognostic significance of the circumferential resection margin following total mesorectal excision... |
|
|
NCI CANCERLIT® Search: Therapy of Colorectal Cancer - September 2002
'Fast track' postoperative management protocol for patients with high co-morbidity undergoing complex abdominal and pelvic colorectal surgery Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its... |
|
|
NCI/PDQ® Health professionals: Colon Cancer Treatment (PDQ®)
TABLE OF CONTENTS General Information About Colon CancerIncidence and MortalityAnatomyRisk FactorsScreeningPrognostic FactorsFollow-upRelated SummariesCellular Classification of Colon CancerStage Information for Colon CancerAJCC Stage Groupings and... |
|
|
NCI/PDQ® Health professionals: Colorectal Cancer Prevention (PDQ®)
TABLE OF CONTENTS Who is at Risk? Overview Factors Associated With Increased Risk of Colorectal Cancer Excessive alcohol useCigarette smokingObesityFactors Associated With a Decreased Risk of Colorectal Cancer Physical activityInterventions... |
|
|
NCI/PDQ® Health professionals: Colorectal Cancer Screening (PDQ®)
TABLE OF CONTENTS Summary of EvidenceSignificanceEvidence of BenefitFecal Occult Blood Test (FOBT)Newer FOBTs: Nonrandomized Controlled Trial EvidenceSigmoidoscopyCombination of FOBT and Flexible SigmoidoscopyBarium EnemaColonoscopyEvidence about... |
|
|
NCI/PDQ® Health professionals: Genetics of Colorectal Cancer (PDQ®)
TABLE OF CONTENTS IntroductionNatural History of CRCMolecular Events Associated With Colon CarcinogenesisFamily History as a Risk Factor for CRCInheritance of CRC PredispositionDifficulties in Identifying a Family History of CRC RiskOther Risk... |
|
|
NCI/PDQ® Health professionals: Rectal Cancer Treatment (PDQ®)
TABLE OF CONTENTS General Information About Rectal CancerIncidence and MortalityEpidemiologyAnatomyRisk FactorsGenetic risk factorsOther risk factorsClinical Presentation and SymptomsClinical Evaluation and StagingTreatmentPrognostic... |
|
|
NCI/PDQ® Pacientes: Cáncer del colon: Tratamiento (PDQ®)
TABLE OF CONTENTS Información general sobre el cáncer del colonEstadios del cáncer del colon Cáncer de colon recidivanteAspectos generales de las opciones de tratamientoOpciones de tratamiento del cáncer del colonEstadio 0... |
|
|
NCI/PDQ® Pacientes: Cáncer del recto: Tratamiento (PDQ®)
TABLE OF CONTENTS Información general sobre el cáncer del rectoEstadios del cáncer de rectoCáncer de recto recidivanteAspectos generales de las opciones de tratamientoOpciones de tratamiento por estadioEstadio 0 (carcinoma in... |
|
|
NCI/PDQ® Patients: Colon Cancer Treatment (PDQ®)
TABLE OF CONTENTS General Information About Colon Cancer Stages of Colon CancerRecurrent Colon CancerTreatment Option OverviewTreatment Options for Colon CancerStage 0 (Carcinoma in Situ)Stage I Colon CancerStage II Colon CancerStage III Colon... |
|
|
NCI/PDQ® Patients: Colorectal Cancer Screening (PDQ®)
TABLE OF CONTENTS What is screening?General Information About Colorectal Cancer Colorectal Cancer ScreeningRisks of Colorectal Cancer ScreeningChanges to This Summary (07/19/2012)Questions or Comments About This SummaryGet More Information From... |
|
|
NCI/PDQ® Patients: Prevention of Colorectal Cancer
TABLE OF CONTENTS Overview of PreventionPreventionPurposes of this summaryColorectal Cancer PreventionSignificance of colorectal cancerColorectal cancer preventionChanges to This Summary (02/20/2007)Questions or Comments About This SummaryTo Learn... |
|
|
NCI/PDQ® Patients: Rectal Cancer Treatment (PDQ®)
TABLE OF CONTENTS General Information About Rectal CancerStages of Rectal CancerRecurrent Rectal CancerTreatment Option OverviewTreatment Options by StageStage 0 (Carcinoma in Situ)Stage I Rectal CancerStage II Rectal CancerStage III Rectal... |
|
|
NCI/PDQ® Profesionales De Salud: Cáncer del colon: Tratamiento (PDQ®)
TABLE OF CONTENTS Información general sobre el cáncer de colonIncidencia y mortalidadFactores pronósticosFactores de riesgoSeguimientoSumarios relacionadosClasificación celular del cáncer de colonInformación sobre los... |
|
|
NCI/PDQ® Profesionales De Salud: Cáncer del recto: Tratamiento (PDQ®)
TABLE OF CONTENTS Información general sobre el cáncer de rectoIncidencia y mortalidadEpidemiologíaAnatomíaFactores de riesgoFactores genéticos de riesgo Otros factores de riesgoPresentación clínica y... |
As an oncologist, Dr. Giantonio provides care for many patients at the end of life, which he describes as a privilege and rewarding. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

